MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/1061186x.2025.2552431

Медицинская библиотека · Journal of drug targeting · 2025

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.

Jiang Qiong, Jin Yanxia, Wang Weidong, Chen Ying, Tian Leyi, Wang Xiaoyu, Wu Aobo, Tian Ruizhi, Pan Jicheng, Gong Yongsheng

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has significantly advanced the treatment of non-small cell lung cancer (NSCLC), particularly in patients who develop resistance to first- and second-generation EGFR-TKIs. However, most patients inevitably develop resistance to the treatment, which presents a major challenge for long-term disease control. The molecular mechanisms underlying osimertinib resistance are complex and are generally categorised into EGFR-dependent and EGFR-independent pathways. To address this issue, various therapeutic strategies have been explored. These include the development of fourth-generation EGFR-TKIs, novel targeted agents and combination therapies involving molecular inhibitors, chemotherapeutic drugs, immunotherapeutic agents and gene inhibitors. In addition, nanomaterials, particularly selenium nanoparticles (SeNPs), have emerged as promising tools to overcome drug resistance. These nanomaterials can be used to enhance osimertinib delivery, improve its bioavailability, and modulate key resistance pathways at the cellular and molecular levels. This review comprehensively summarises the current understanding of resistance mechanisms to osimertinib and highlights cutting-edge therapeutic approaches. Special attention is given to nanotechnology-based strategies, which offer new possibilities for personalised and precise treatment of NSCLC. A deeper insight into these molecular mechanisms is essential for improving the clinical efficacy of osimertinib and prolonging the survival of patients with EGFR-mutant NSCLC.

Для цитирования: Jiang Qiong, Jin Yanxia, Wang Weidong, Chen Ying, Tian Leyi, Wang Xiaoyu, Wu Aobo, Tian Ruizhi, Pan Jicheng, Gong Yongsheng. Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.. Journal of drug targeting. 2025. DOI: 10.1080/1061186x.2025.2552431.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.